11 June 2018

Under the name TopFit Impact Programme, Radboudumc, Radboud University, the University of Twente and Wageningen University & Research, join together in an impact programme aimed at preventing and reducing disease and the burden of disease.

Framework

Much progress has been made in recent years in understanding disease processes and the development of new treatment methods. At the same time, the realization that many diseases will remain incurable for the foreseeable future grows. Through smart integration of innovative technologies and knowledge about nutrition and health we can be one step ahead of disease and its burdens.

These integral solutions mean that there will be an ever more personal approach in healthcare. The payoff is a maximum increase in the quality of life of patients and the best perspective on affordable healthcare in an aging society. The goal of the TopFit programme is to contribute to controlling and limiting the cost of healthcare in the future, without making concessions to the quality of life of patients.

Impact

TopFit aspires to be a leading health impact programme on three levels: society & health, innovation & (regional) economy and science & technology. Therefore, the researchers work together with key partners in the east of the Netherlands.

During the summer of 2018 the programme will be further specified. After that, more information about TopFit will be available.

Contact

Are you interested in the TopFit Impact Programme? Do you want to be involved or do you have questions? Please contact Nathalie Bovy-vanderLugt.
 

Related news items


Frank Walboomers 25-years work anniversary at Radboudumc

17 September 2020

Frank Walboomers, associate professor at the research group Regenerative Biomaterials at the Dept. of Dentistry (theme Reconstructive & Regenerative Medicine), celebrated his 25th work anniversary at Radboudumc.

read more

Tjitske Kleefstra appointed endowed professor of Clinical genetics and psychopathology of rare syndromes

17 September 2020

Tjitske Kleefstra has been appointed endowed professor of Clinical genetics and psychopathology of rare syndromes at the department of Neurodevelopmental disorders, with effect from 1 September.

read more

Annette Schenck appointed professor of Translational Genetics

17 September 2020

Annette Schenck has been appointed professor of Translational Genetics at the department of Neurodevelopmental disorders, with effect from 1 August. The chair will bring together fundamental and translational research in the field of brain developmental disorders.

read more

Centuries-old medicine reduces the risk of new cardiovascular disease in heart patients

17 September 2020

Colchicine, an anti-inflammatory drug that has been used for gout for centuries, has been shown to prevent cardiovascular disease in patients who have had a heart attack or are suffering from narrowed coronary arteries. Results of the study are published in the New England Journal of Medicine.

read more

Radboudumc does large-scale research on systemic sclerosis

10 September 2020

In rare diseases, such as systemic sclerosis, it’s often difficult to conduct large-scale research. Rheumatologist Madelon Vonk has managed to follow enough patients with systemic sclerosis for years. The results of her research have been published in BMJ Annal of the Rheumatic Diseases.

read more